Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.53 |
| ▸ | BAD | Q92934 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPN | P05981 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264072 | 0.84 | BCL2L1 (0.53) | BCL2L1BADCYP2A6MEN1USP2 | |
| SCHEMBL25300354 | 0.83 | CYP1A2 (0.52) | BCL2L1BADCYP2A6MEN1USP2 | |
| SCHEMBL29414699 | 0.78 | — | — | |
| SCHEMBL150017 | 0.78 | — | — | |
| SCHEMBL1276263 | 0.78 | DRD2 (0.56) | BCL2L1BADCYP2A6MEN1USP2 | |
| Formaldehyde SCHEMBL17491106 | 0.77 | BCL2L1 (0.65) | BCL2L1BADMEN1USP2ALDH1A1 | |
| SCHEMBL1662187 | 0.76 | CYP2A6 (0.52) | CYP2A6MEN1KMT2AHSD17B10TDP1 | |
| SCHEMBL8061942 | 0.76 | CYP2A6 (0.52) | CYP2A6MEN1KMT2ADRD2DRD3 | |
| SCHEMBL14220348 | 0.76 | CYP2A6 (0.52) | CYP2A6MEN1USP2ALDH1A1HPN | |
| SCHEMBL7333315 | 0.76 | CYP2A6 (0.52) | CYP2A6MEN1ALDH1A1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113336633-B | Synthetic method of 5-hydroxy-2-tetralone | 武汉工程大学 | 2022-12-06 | — | — | CN | claimed |
| CN-113336633-A | Synthetic method of 5-hydroxy-2-tetralone | 武汉工程大学 | 2021-09-03 | — | — | CN | claimed |
| EP-3409658-B9 | TETRAHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3409658-B1 | TETRAHYDRONAPHTHALENE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2024-03-06 | — | — | EP | disclosed |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| CN-113336633-B | Synthetic method of 5-hydroxy-2-tetralone | 武汉工程大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-113336633-B | Synthetic method of 5-hydroxy-2-tetralone | 武汉工程大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-113336633-B | Synthetic method of 5-hydroxy-2-tetralone | 武汉工程大学 | 2022-12-06 | — | — | CN | disclosed |
| CN-1756746-A | 6-substituted nicotinamide derivatives as opioid receptor antagonists | LILLY CO ELI (US) | 2006-04-05 | — | — | CN | disclosed |
| EP-1613597-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004080968-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| WO-1995002575-A1 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0522000-A1 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-13 | — | — | EP | disclosed |
| WO-1991014674-A2 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
| US-4156789-A | INTERMEDIATES, ANTIFIBRILLATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1979-05-29 | — | — | US | disclosed |
| US-3982021-A | Compositions for the treatment of coronary diseases containing tetrahydronaphthyloxy-aminopropanols | E. R. SQUIBB & SONS, INC. (US) | 1976-09-21 | — | — | US | disclosed |
| US-3935267-A | CARDIOVASCULAR DISORDERS | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | BCL2L1 4780/4885BAD 4674/4885CYP2A6 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.